SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-228444
Filing Date
2023-09-05
Accepted
2023-09-05 15:11:56
Documents
2
Group Members
ALBERT CHADANIEL ESTESFHMLS IX, L.L.C.FHMLS IX, L.P.FHMLS X, L.L.C.FHMLS X, L.P.FHMLS XI, L.L.C.FHMLS XI, L.P.FHMLSP OVERAGE, L.L.C.FHMLSP OVERAGE, L.P.FHMLSP, L.L.C.FHMLSP, L.P.FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.FRAZIER LIFE SCIENCES PUBLIC OVERAGE F

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d545032dsc13da.htm SC 13D/A 508315
2 EX-99.A d545032dex99a.htm EX-99.A 34376
  Complete submission text file 0001193125-23-228444.txt   544877
Mailing Address 601 UNION STREET SUITE 3200 SEATTLE WA 98101
Business Address 601 UNION STREET SUITE 3200 SEATTLE WA 98101 206-254-7200
Frazier Life Sciences IX, L.P. (Filed by) CIK: 0001720320 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404
Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Subject) CIK: 0001759425 (see all company filings)

IRS No.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91075 | Film No.: 231235353
SIC: 2834 Pharmaceutical Preparations